Biogen's 2022 outlook leaves investors wanting, shares slip
Biogen expects "minimal" sales this year from its Alzheimer's treatment initially hailed as a potential breakthrough drug, but one with an eye-popping price that drew immediate cri…
Biogen expects "minimal" sales this year from its Alzheimer's treatment initially hailed as a potential breakthrough drug, but one with an eye-popping price that drew immediate cri…